Sign in

You're signed outSign in or to get full access.

Vernon Rogers

Executive Vice President of Sales and Marketing at AEHR TEST SYSTEMSAEHR TEST SYSTEMS
Executive

About Vernon Rogers

Vernon Rogers is Executive Vice President of Sales and Marketing at Aehr Test Systems; he joined in October 2018 and was listed among executive officers in the 2025 proxy (age 58) . He holds a B.S. in Electrical Engineering from North Dakota State University and has spent over two decades in senior sales, marketing and operations roles across semiconductor test and system-level test markets . Company performance context during his tenure: Aehr’s total shareholder return (TSR) index (fixed $100 base) moved from 394 (FY2023) to 512 (FY2024) and then 114 (FY2025), with net income of $14.6M (FY2023), $33.2M (FY2024), and a $(3.9)M loss (FY2025) .

Past Roles

OrganizationRoleYearsStrategic Impact
Global Equipment Services (later acquired by Averna)Head of Sales and MarketingNot disclosedLed sales/marketing; foundation for subsequent EVP Sales & Marketing role at Aehr .
LitePoint (acquired by Teradyne)Senior sales/marketing rolesNot disclosedBuilt multi-channel sales distribution and support in wireless test solutions .
Credence Systems (acquired by Xcerra)Senior sales/marketing rolesNot disclosedSemiconductor automated test equipment sales leadership .
NPTest (acquired by Credence)Senior sales/marketing rolesNot disclosedSemiconductor test equipment sales leadership .
Schlumberger Automated Test EquipmentSenior sales/marketing rolesNot disclosedNanoscale inspection/manufacturing/test solutions .
FlexStar TechnologySales oversightNot disclosedHDD/SSD test and burn-in sales oversight .

Fixed Compensation

  • FY2024 base salary: $283,500 .
  • FY2024 personal performance cash bonus: Target $90,000; paid $42,360 .
  • FY2024 company performance cash bonus: Maximum opportunity up to 45.9% of base salary; paid $0 given results .
  • FY2024 booking commissions: $48,773 under plan (0.1% on bookings ≤$120M; 2x rate above $120M) .
  • FY2024 “All Other Compensation”: $67,595, including health/life/medical $46,624, ESOP contribution $8,771, auto allowance $12,000 .

Multi-year summary (amounts are those reported in Summary Compensation Table):

MetricFY2023FY2024
Salary ($)268,561 296,311
Stock Awards ($)216,000 184,698
Non-Equity Incentive Comp ($)159,195 106,764
All Other Compensation ($)66,640 67,595
Total ($)710,396 655,368

Performance Compensation

  • Booking commission plan evolution and realized commissions:
Fiscal YearPlan MechanicsRealized Commissions ($)
FY20220.375% up to 100% of bookings quota; 0.75% above quota; paid upon revenue recognition month close 320,377
FY20230.108% existing customers; 0.216% new customers up to quota; double rates above quota; paid following month 100,230
FY20240.1% up to $120M bookings; double above $120M; paid following month 48,773
  • FY2024 annual bonus structure and outcomes:
ComponentWeighting/OpportunityTargetActual/PayoutNotes
Company performance bonusUp to 45.9% of base salary Not quantified in $0No payout based on FY2024 results .
Personal performance bonusTarget cash90,000 42,360 Discretionary, based on milestones .
  • Equity incentives (granted FY2024 cycle on Oct 27, 2023):
    • Time-based RSUs: 6,200 RSUs vesting 1/16 quarterly over 4 years .
    • Performance RSUs: 5,167 target RSUs vesting 100% upon achieving cumulative revenue target by May 31, 2026; service condition through achievement date .

Vesting conventions:

  • RSUs generally vest 1/16 quarterly over 4 years; performance RSUs vest on goal achievement timelines per grant .
  • Stock options (legacy grants) vest 1/48 monthly over 4 years; 10-year term .

Equity Ownership & Alignment

  • Beneficial ownership trend:
As-of DateShares Beneficially OwnedOwnership %
Aug 31, 2022236,658 <1%
Aug 25, 2023158,685 <1%
Aug 23, 2024170,215 <1%
  • Near-term vested/vesting breakdown (as of Aug 23, 2024): includes 150,468 options exercisable within 60 days and 3,653 RSUs vesting within 60 days .
  • Hedging/pledging policy: Company prohibits hedging, short sales, and pledging/margin of company stock for insiders, including named executive officers .
  • Clawback: Executive compensation is subject to a Dodd-Frank-compliant clawback policy adopted Aug 14, 2023 and filed as Exhibit 97.1 to the FY2025 Form 10-K .

Outstanding and Vesting Equity Detail (as of FY2024 year-end)

Grant/InstrumentStatus at 5/31/2024Shares/OptionsStrike/ValueVesting/Expiry
Stock options (10/23/2018)Exercisable/Unexercisable110,283 / 185 $2.03Exp. 10/23/2025
Stock options (7/16/2019)Exercisable (two tranches)15,262 / 24,738 $1.635Exp. 7/16/2026
RSUs (7/14/2020)Unvested1,263$14,537 market value at $11.51 close 1/16 quarterly
RSUs (7/13/2021)Unvested4,199$48,330 market value 1/16 quarterly
RSUs (7/14/2022)Unvested (time-based)10,125$116,539 market value 1/16 quarterly
RSUs (7/14/2022)Unvested (perf.-linked tranche)5,061$58,252 market value Perf. gate then 1/16 thereafter
RSUs (10/27/2023)Unvested (time-based)5,425$62,442 market value 1/16 quarterly
RSUs (10/27/2023)Unvested (performance)5,167 target$59,472 market value 100% upon cumulative revenue target by 5/31/2026

Note: Market values use $11.51 closing price on 5/31/2024 as disclosed; vesting conventions per footnotes .

Employment Terms

  • Role and start date: Joined Aehr as EVP Sales & Marketing in October 2018 .
  • Change-in-control and severance (executed Aug 31, 2024 for Rogers):
    • Qualifying termination during CIC period (3 months before to 12 months after CIC for Rogers): cash equal to 12 months base salary; 100% of target annual cash incentive; pro-rata target bonus for year of termination; full acceleration of time-based equity; performance equity deemed at the greater of target or expected attainment; up to 12 months Company-paid healthcare .
    • Qualifying termination outside CIC: 6 months base salary; pro-rata target bonus; 6 months’ acceleration of unvested equity (performance at target); up to 6 months healthcare .
  • Clawback: Covered under Company’s recovery policy (see above) .
  • Non-compete/non-solicit: Not disclosed in proxy .

Performance & Track Record Context

Fiscal YearTSR Index (Fixed $100 Base)Net Income ($000s)
2023394 14,557
2024512 33,156
2025114 (3,910)
  • Compensation program emphasizes at-risk pay; commissions, performance cash, and performance RSUs tie earnings to bookings and cumulative revenue targets; prohibition on hedging/pledging supports alignment with shareholders .
  • Legacy option grants carried expirations in Oct 2025 and July 2026, which historically can create exercise/settlement activity around expirations; the Company’s insider trading policy requires pre-clearance and prohibits hedging/pledging .

Compensation Structure Analysis

  • Mix and evolution:
    • Shift toward RSUs: FY2024 and FY2023 grants to Rogers were RSUs (time-based and performance-based); no new options to NEOs in FY2025; company notes RSUs predominant in recent cycles .
    • Variable cash moderated with results: Booking commissions fell from $320,377 (FY2022) to $100,230 (FY2023) to $48,773 (FY2024) as plan mechanics and bookings evolved .
    • Discretion retained: Personal performance bonuses paid despite no company performance bonus in FY2024 ($42,360 to Rogers) .
  • Governance protections: Explicit prohibition on hedging/pledging and a compliant clawback policy mitigate misalignment and recoup risk .

Investment Implications

  • Pay-for-performance linkage is tangible via commissions and performance RSUs on cumulative revenue, creating sensitivity to bookings momentum; declining commissions from FY2022 to FY2024 reflect tighter linkage to business trends .
  • Retention risk appears moderate: Rogers has double-trigger CIC protection (12 months salary plus 100% target bonus and equity acceleration in a CIC termination window), and ongoing time-based/performance RSU vesting supports tenure incentives .
  • Alignment signals are positive: strict prohibitions on hedging/pledging and an active clawback framework reduce adverse incentives; however, legacy option expirations (2025–2026) historically can create exercise-related trading windows that investors should watch around vesting/expiry cycles .